Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
90Y-hMN14 in Refractory Metastatic/Recurrent Colorectal Cancer
NCT00040599Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jan 2000
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of yttrium-90 labetuzumab in colorectal cancer (CRC), sponsored by Gilead Sciences. Started Jan 2000; status: completed.
02
Drugs
yttrium-90 labetuzumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT00040599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00040599.